E-Book

E-Book 2nd Congress

  • neuroinflammatory chemokines in COVID-19 neurologic complications
  • mahin behzadifard,1,* roqaye karimi,2
    2. Tarbiat Modares univercity


  • Introduction: The neurologic complications in COVID-19 patients comprise symptoms including depression, anxiety, muscle pain, dizziness, headaches, fatigue, and anosmia/hyposmia that may continue for months. Recent studies have been demonstrated that chemokines have brain-specific attraction and effects such as chemotaxis, cell adhesion, modulation of neuroendocrine functions, and neuroinflammation. CCL11 is a member of the eotaxin family that is chemotactic agents for eosinophils and participate in innate immunity. Eotaxins may exert physiological and pathological functions in the central nerve system, and CCL11 may induce neuronal cytotoxicity effects by inducing the production of reactive oxygen species (ROS) in microglia cells.
  • Methods: To provide a better prospect representing in ccl11 chemokine and and neuroinflammation in COVID-19, we searched national library of medicine Medline/PubMed and google scholar using the keywords "CCL11 "AND “COVID-19” OR “coronavirus 2019” OR “2019-nCoV” OR “SARSCoV-2” between December, 2019 and the time of our analysis (i.e., Agust, 2021), without any restriction.
  • Results: Plasma levels of CCL11 elevated in neuroinflammation and neurodegenerative disorders. COVID-19 patients display elevations in CCL11 levels.
  • Conclusion: As CCL11 plays roles in physiosomatic and neuroinflammation, analyzing the level of this chemokine in COVID-19 patients during hospitalization and to predicting post-COVID-19-related neurologic complications may be worthwhile. Moreover, using chemokine modulators may be helpful in lessening the neurologic complications in such patients.
  • Keywords: CCL11;Neuroinflammation; COVID-19; Eotaxin-1; SARS-CoV-2.